Advertisement

Invacare must address a few more issues before landing certification, a 3rd-party auditor tells company executives.

Invacare provides update on FDA consent decree

Invacare (NYSE:IVC) has a few more items to address before winning certification for its Ohio facility, a 3rd-party auditor told company executives.

Although the company has made "significant progress" in addressing the FDA's quality control concerns, Invacare remains under a consent decree that has since last year limited its research, development and manufacturing abilities.

Advertisement
Advertisement